# A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Study · id `cardio:ct-nct07107945` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07107945](<https://clinicaltrials.gov/study/NCT07107945>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07107945

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 135 participants.

## Technical summary

Registry record NCT07107945. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-09 (actual); primary completion 2027-04-16 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 135 participants (enrolled count; ClinicalTrials.gov record NCT07107945, source copy `cardio:ctgov-nct07107945-2026-11-10`, retrieved 2026-11-18)
- Started: 2025-12-09 (actual) (ClinicalTrials.gov record NCT07107945, source copy `cardio:ctgov-nct07107945-2026-11-10`, retrieved 2026-11-18)
- Primary completion: 2027-04-16 (anticipated) (ClinicalTrials.gov record NCT07107945, source copy `cardio:ctgov-nct07107945-2026-11-10`, retrieved 2026-11-18)
- Completion: 2028-04-14 (anticipated) (ClinicalTrials.gov record NCT07107945, source copy `cardio:ctgov-nct07107945-2026-11-10`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Belgium; Canada; France; Germany; Hungary; Italy; Netherlands; Poland; Portugal; Singapore; South Korea; Spain; Sweden; Türkiye; United Kingdom (ClinicalTrials.gov record NCT07107945, source copy `cardio:ctgov-nct07107945-2026-11-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07107945-2026-11-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
- Condition: Chronic Kidney Disease
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 31fe576e20d2f88906a01b9233881c37f615a86ec56b5541e19d4abbe2173765
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
